截至本公告披露日，公司最近五年不存在被证券监管部门和交易所处罚的情 况。 二、最近五年被证券监管部门和交易所采取监管措施及整改的情况 限公司控股股东罗卫国予以通报批评的决定》（上海证券交易所纪律处分决定书 〔2022〕17 号），公司控股股东罗卫国与一致行动人持股比例因公司非公开发行 股票被动稀释变动达到总股本 8.33%后又主动减持，因未按规定及时履行相关权 益变动披露义务，违反了《上海证券交易所股票上市规则》等有关规定，上海证 券交易所对控股股东罗卫国予以通报批评的纪律处分决定。 整改情况：罗卫国先生承诺，将会加强相关法律、法规和制度的学习，杜绝 此类错误再次发生。 证券代码：603717 证券简称：天域生物 公告编号：2025-068 天域生物科技股份有限公司 关于最近五年被证券监管部门和交易所采取监管措施或处 罚情况及及整改情况的公告 本公司及其董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日召开 了公司第四届董事会第四十三次会议、第四届监事会第三 ...

Core Viewpoint - LiuZhou Chemical Co., Ltd. received a corrective order from the Guangxi Securities Regulatory Bureau, requiring the company to rectify identified issues within 30 days and submit a report on the corrective actions taken [1]. Summary by Sections Issues Identified and Corrective Measures - The company acknowledged issues related to non-compliance in accounting practices, specifically inaccurate revenue and cost recognition in financial reports, violating the "Management Measures for Information Disclosure of Listed Companies" [1]. - Corrective actions include adjusting previous accounting errors by changing the revenue recognition method from gross to net, with restated financial statements disclosed [2]. - The impact of the adjustments on financial statements includes a reduction in operating revenue and costs across multiple reporting periods, with specific figures provided for each period [2][3]. Completion of Rectification - The company has completed the necessary corrections and will continue to enhance the quality of financial reporting to prevent similar issues in the future [3]. - The responsible parties for the rectification include the Chairman, General Manager, Board Secretary, and Financial Officer [3]. Compliance with Regulatory Requirements - The company has fulfilled its obligation to check the integrity records of its appointed directors and senior management, addressing previous lapses in compliance [4]. - The company emphasizes ongoing adherence to relevant laws and regulations, aiming to improve governance and internal control processes [4]. Future Plans and Continuous Improvement - The company views the regulatory inspection as an opportunity to enhance operational standards and financial accounting practices [4]. - Future initiatives include regular internal audits, risk assessments, and ensuring compliance with securities market laws to safeguard shareholder interests and promote sustainable development [4].

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Core Viewpoint - Ruida Futures has received regulatory warnings and penalties from the Xiamen Securities Regulatory Bureau due to accounting irregularities related to revenue recognition, which have led to inaccurate financial disclosures [2][4][5]. Group 1: Regulatory Actions - The Xiamen Securities Regulatory Bureau issued a warning letter to Ruida Futures and mandated disciplinary actions against responsible personnel, including the chairman, general manager, CFO, and chief risk officer [2][4]. - The regulatory measures include increased internal compliance checks and recording the situation in the securities market integrity archives [4][5]. Group 2: Accounting Issues - Ruida Futures' subsidiary, Ruida New Control Capital Management Co., Ltd., was found to have non-compliant accounting practices, specifically regarding revenue recognition for certain trade-related business activities [4]. - The company has corrected prior accounting errors in accordance with relevant accounting standards and has fulfilled its information disclosure obligations [5]. Group 3: Financial Impact - As a result of the accounting issues, Ruida Futures adjusted its revenue recognition method for 2022, leading to a decrease in reported revenue by 77.21 million yuan, revising it to 2.029 billion yuan [5]. - The company reported a significant increase in revenue for 2024, achieving 1.81 billion yuan, a year-on-year growth of 95.45%, and a net profit of 383 million yuan, up 56.93% [6].

Core Viewpoint - The Xiamen Securities Regulatory Bureau issued warning letters to the chairman, general manager, CFO, and chief risk officer of Ruida Futures due to inadequate internal control and accounting irregularities in its subsidiary, leading to inaccurate financial disclosures [1][4]. Group 1: Regulatory Actions - Ruida Futures and its responsible personnel received warning letters from the Xiamen Securities Regulatory Bureau for failing to fulfill their duties as per relevant regulations [4][5]. - The regulatory body mandated increased internal compliance checks and recorded the situation in the securities market integrity archives [4]. Group 2: Financial Performance - In Q1 2025, Ruida Futures reported a revenue of 383 million yuan, a year-on-year increase of 36.86%, and a net profit attributable to shareholders of 81.06 million yuan, up 12.01% [5]. - For the year 2024, the company achieved a revenue of 1.81 billion yuan, representing a growth of 95.45%, with a net profit of 383 million yuan, an increase of 56.93% [5]. Group 3: Company Background - Established in 1993, Ruida Futures is a large fully licensed futures company in China, with over 40 branches nationwide [5].